skip to primary navigationskip to content
 

Professor Nick Morrell

Professor Nick Morrell

BHF Professor of Cardiopulmonary Medicine

Research Director, National Pulmonary Hypertension Service, Papworth Hospital


Office Phone: 01223 331666

Research Interests

Genetics, epidemiology and cell biology of pulmonary hypertension

We study the molecular mechanisms underlying pulmonary arterial hypertension (PAH). In particular, our research focuses on how mutations in the bone morphogenetic protein type II receptor (BMPR-II), a receptor member of the transforming growth factor-beta superfamily, cause familial PAH.

Our research is revealing how BMPR-II mutation leads to dysfunctional signalling, gene transcription and vascular cell biology. This work has also revealed a broader role for BMPR-II in angiogenesis, inflammation, iron metabolism and innate immunity.

Our research has suggested new approaches to the rescue of BMPR-II deficiency. These include gene therapy, enhanced BMPR-II transcription and the demonstration that BMPR-II is rapidly degraded by the lysosome. Inhibition of the lysosomal turnover of BMPR-II with agents such as chloroquine increase cell surface BMPR-II and are effective in experimental models of pulmonary hypertension.

Using structural biology approaches (Dr Wei Li) we are defining the molecular interaction between bone morphogenetic protein ligands and receptors. The BMP9/BMPR-II/ALK-1 complex is the focus of these studies. The aim is to develop designer peptides or small molecules that enhance BMPR-II signalling specifically in the vasculature.

We are using induced pluripotent stem cells derived from patients with gain and loss of function in BMP pathways (Dr Amer Rana) to understand the impact of BMPs on heart and blood vessel development and function.

Our research is demonstrating the broader role of the BMP pathway in vascular disease and providing new insights into the pathogenesis of other conditions, including atherosclerosis.

National Pulmonary Hypertension Service

Our group has close links with the National Pulmonary Hypertension Service at Papworth Hospital, where Professor Morrell is the Research Director. We are employing next generation sequencing in our cohort of patients to define the genetic architecture of PAH, which may reveal further tractable targets for therapy. Our clinical research team has identified novel biomarkers for predicting survival in PAH patients and we are assessing better ways to measure response to therapy in patients using imaging techniques (MRI/CT) and physiological measurements of exercise and gas exchange. We have an active translational research programme at Papworth where new targets identified from basic science studies can be trialed for the first time in patients with severe PAH.

Keywords

genetics ; cell biology ; molecular biology ; pulmonary hypertension ; stem cells ; right heart failure

Key Publications

Most recent publications are listed on PubMed.

1.     Long L, Ormiston ML, Yang XD, Southwood M, Graf S, Machado RD, Mueller M, Kinzel B, Yung LM, Wilkinson JM, Moore SD, Drake KM, Aldred MA, Yu PB, Upton PD, Morrell NW. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nature Medicine 2015;21(7):777-85.

2.     Evans JD, Girerd B, Montani D, Wang XJ, Galiè N, Austin ED, Elliott G, Asano K, Grünig E, Yan Y, Jing ZC, Manes A, Palazzini M, Wheeler LA, Nakayama I, Satoh T, Eichstaedt C, Hinderhofer K, Wolf M, Rosenzweig EB, Chung WK, Soubrier F, Simonneau G, Sitbon O, Gräf S, Kaptoge S, Di Angelantonio E, Humbert M, Morrell NW. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med. 2016;4:129-37. 

3.     Rhodes CJ, Ghataorhe P, Wharton J, Rue-Albrecht KC, Hadinnapola C, Watson G, Bleda M, Haimel M, Coghlan G, Corris PA, Howard LS, Kiely DG, Peacock AJ, Pepke-Zaba J, Toshner MR, Wort SJ, Gibbs JS, Lawrie A, Gräf S, Morrell NW, Wilkins MR. Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. Circulation. 2017;135(5):460-475.

4.     Hurst LA, Dunmore BJ, Long L, Crosby A, Al-Lamki R, Deighton J, Southwood M, Yang X, Nikolic MZ, Herrera B, Inman GJ, Bradley JR, Rana AA, Upton PD, Morrell NW.TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling. Nat Commun. 2017 Jan 13;8:14079.

 

Logo design by Dr Ana-Mishel Spiroski and Dr Sarah Morgan.

 

We connect cardiovascular researchers in Cambridge.

Please follow us on Twitter for local news about research, events, funding calls, and open positions.

For inquiries about our research or the website, please contact Dr Katja Kivinen.